|
DU-145 derived prostate-carcinoma microtissues
Origin
hPr-CCL01MT microtissues are formed by DU-145 human prostate carcinoma cells. This cell line was established from a metastatic central nervous system lesion of a patient with a prostate carcinoma in 1975 (Mickey DD et al., 1980, Prog Clin Biol Res.). The DU-145 cells were obtained from DSMZ (German Collection of Microorganisms and Cell Cultures).
From 2D to 3D. Microtissue formation and growth
DU-145 cells from a monolayer culture were trypsinized and 1000 cells were seeded per drop. Pictures were taken of the monolayer culture (2D) and of the microtissues at day 1, 4 and 12 after seeding.
Microtissue growth and drug sensitivity
(A) DU-145 cells from a monolayer culture were trypsinized and 1000 cells were seeded per drop. Microtissue size and ATP content were measured at day 5, 6, 11, 13 and 15 after seeding. (B) Microtissues at day 4 were treated for 3 days with indicated concentrations of taxol (0.1% DMSO). ATP content was measured as a viability indicator and normalized to the DMSO only treated control.
Histological Analysis
hLi-CCL01MT were fixed and embedded into paraffin blocks at day 6 after seeding. Paraffin sections were stained with H&E (A) and for Ki67 (B).
Specification
|
| Microtissue type |
Prostate cancer cell line (DU-145 derived) microtissue |
| MT growth medium |
DMEM + supplements |
| Delivery format |
non-adhesive 96-well V-bottom plate, room temperature |
| Initial cell number per microtissue |
1000 |
| Microtissue growth prior delivery |
4-6 days |
| Microtissue size upon delivery |
100-250 μm in diameter |
| Tissue growth rate |
fast after lag phase of 6-7 days |
| Mycoplasm |
negative in MycoAlert assay |
| Viruses (tested by cell supplier) |
ELISA: reverse transcriptase negative;
PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV -, HTLV-I/II -, SMRV - |
|
